The clinical value of inhibiting EGFR signalling with TKIs has been confirmed with the EGFR TKIs gefitinib (IressaTM) and erlotinib (TarcevaTM), which are approved for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Here, EGFR is linked to non-small cell lung carcinoma.